Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00953758 · ClinicalTrials.gov registry record · Phase 1
A Study Of PF-04449913 In Select Hematologic Malignancies
A Phase 1 study of Hematologic Malignancies, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 6
- Study locations
NCT00953758 is a Phase 1 study of Hematologic Malignancies that has completed, run by Pfizer. The registered enrollment target is 47 participants, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT00953758, a Phase 1 study of Hematologic Malignancies, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select hematologic malignancies.
Conditions Studied
Interventions
- DRUG PF-04449913
Study Locations (6)
California
- UCSD Medical Center - La Jolla - La Jolla
- Moores UCSD Cancer Center - La Jolla
- UCSD Medical Center - Hillcrest - San Diego
Texas
- The University of Texas M.D. Anderson Cancer Center - Houston
Washington
- University of Washington Medical Center, Seattle Cancer Care Alliance - Seattle
Other
- U.O. di Ematologia - Bologna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2010-03-03 |
| Est. Completion | 2013-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00953758
The ClinicalTrials.gov registry entry for NCT00953758 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (98% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which PF-04449913 is the first listed.
NCT00953758 reports 6 study locations spanning 4 distinct geographic areas - top geographies include California, Texas, Washington.
Frequently Asked Questions
What is clinical trial NCT00953758 about?
NCT00953758 is a clinical study titled "A Study Of PF-04449913 In Select Hematologic Malignancies". This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select hematologic malignancies.
What is the current status of trial NCT00953758?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2010-03-03. Estimated completion is 2013-02-27.
What conditions does trial NCT00953758 study?
This clinical trial studies the following conditions: Hematologic Malignancies.
What interventions are being tested in trial NCT00953758?
The interventions under investigation include: PF-04449913 (DRUG).
Who is sponsoring clinical trial NCT00953758?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00953758 being conducted?
This trial has 6 study locations across California, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
-
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
-
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.